Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential involvement of the senses in disgust memories.
Lamond E, Saluja S, Hislop C, J Stevenson R. Lamond E, et al. Among authors: hislop c. R Soc Open Sci. 2024 Mar 20;11(3):231156. doi: 10.1098/rsos.231156. eCollection 2024 Mar. R Soc Open Sci. 2024. PMID: 38550756 Free PMC article.
Diagnostic Accuracy and economic value of a Tiered Assessment for Fetal Alcohol Spectrum Disorder (DATAforFASD): Protocol.
Shanley DC, Zimmer-Gembeck M, Wheeler AJ, Byrnes J, Ware RS, Liu W, Simcock G, White C, Horton S, Page M, Shelton D, Till H, Mills I, Hislop C, Harris K, Crichton A, Reid N, Reilly S, Moritz K, Walsh K, Rundle-Thiele S, Hawkins E. Shanley DC, et al. Among authors: hislop c. BMJ Open. 2023 Aug 16;13(8):e071004. doi: 10.1136/bmjopen-2022-071004. BMJ Open. 2023. PMID: 37586864 Free PMC article.
Report of the "Women in Academic Spine" Initiative.
Koshinski JL, Xiong GX, Agaronnik N, Byrd C, Call CM, Enchill Z, Giberson-Chen C, Hering K, Hislop C, McGovern MM, Parker A, Schoenfeld AL, Yuen LC, Ihejirika-Lomedico R, Lipa SA. Koshinski JL, et al. Among authors: hislop c. Spine (Phila Pa 1976). 2023 Apr 15;48(8):515-518. doi: 10.1097/BRS.0000000000004608. Epub 2023 Feb 14. Spine (Phila Pa 1976). 2023. PMID: 36799734 No abstract available.
Early Treatment with Pegylated Interferon Lambda for Covid-19.
Reis G, Moreira Silva EAS, Medeiros Silva DC, Thabane L, Campos VHS, Ferreira TS, Santos CVQ, Nogueira AMR, Almeida APFG, Savassi LCM, Figueiredo-Neto AD, Dias ACF, Freire Júnior AM, Bitarães C, Milagres AC, Callegari ED, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Wilson LA, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Limbrick-Oldfield EH, Kanters S, Guyatt GH, Rayner CR, Kandel C, Biondi MJ, Kozak R, Hansen B, Zahoor MA, Arora P, Hislop C, Choong I, Feld JJ, Mills EJ, Glenn JS; TOGETHER Investigators. Reis G, et al. Among authors: hislop c. N Engl J Med. 2023 Feb 9;388(6):518-528. doi: 10.1056/NEJMoa2209760. N Engl J Med. 2023. PMID: 36780676 Free PMC article. Clinical Trial.
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.
Jagannathan P, Andrews JR, Bonilla H, Hedlin H, Jacobson KB, Balasubramanian V, Purington N, Kamble S, de Vries CR, Quintero O, Feng K, Ley C, Winslow D, Newberry J, Edwards K, Hislop C, Choong I, Maldonado Y, Glenn J, Bhatt A, Blish C, Wang T, Khosla C, Pinsky BA, Desai M, Parsonnet J, Singh U. Jagannathan P, et al. Among authors: hislop c. Nat Commun. 2021 Mar 30;12(1):1967. doi: 10.1038/s41467-021-22177-1. Nat Commun. 2021. PMID: 33785743 Free PMC article. Clinical Trial.
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.
Feld JJ, Kandel C, Biondi MJ, Kozak RA, Zahoor MA, Lemieux C, Borgia SM, Boggild AK, Powis J, McCready J, Tan DHS, Chan T, Coburn B, Kumar D, Humar A, Chan A, O'Neil B, Noureldin S, Booth J, Hong R, Smookler D, Aleyadeh W, Patel A, Barber B, Casey J, Hiebert R, Mistry H, Choong I, Hislop C, Santer DM, Lorne Tyrrell D, Glenn JS, Gehring AJ, Janssen HLA, Hansen BE. Feld JJ, et al. Among authors: hislop c. Lancet Respir Med. 2021 May;9(5):498-510. doi: 10.1016/S2213-2600(20)30566-X. Epub 2021 Feb 5. Lancet Respir Med. 2021. PMID: 33556319 Free PMC article. Clinical Trial.
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA; PEARL-SC Study. Furie RA, et al. Among authors: hislop c. Ann Rheum Dis. 2015 Sep;74(9):1667-75. doi: 10.1136/annrheumdis-2013-205144. Epub 2014 Apr 19. Ann Rheum Dis. 2015. PMID: 24748629 Clinical Trial.
19 results